Do you have to start Mounjaro at 2.5 mg, or can you begin on a higher dose?

The myth: starting higher gets results faster

It's a reasonable assumption. If Mounjaro 15 mg produces greater average weight reduction than 2.5 mg, surely beginning at 5 mg or 7.5 mg would accelerate things? The evidence doesn't support that reasoning, and the licensed prescribing information for tirzepatide is unambiguous: treatment begins at 2.5 mg for four weeks, full stop.

The reason is largely physiological. GIP and GLP-1 receptor agonists slow gastric emptying and alter appetite signalling; when those effects arrive too quickly, nausea, vomiting and other gastrointestinal symptoms can be severe enough to force people off treatment entirely. The graduated schedule isn't a formality, it's the mechanism by which most people reach the doses where meaningful weight loss happens. You can read the detailed dosing rationale in the Mounjaro SmPC on the eMC, which sets out the full licensed titration pathway.

People sometimes arrive at our service having read online that a clinic elsewhere offered them 5 mg to start. A closer look at whether starting at 5 mg is ever appropriate explains why reputable prescribers don't do this, and what it signals when one does. The short answer: it isn't appropriate, and the licensed prescribing information makes that clear.

What 2.5 mg is actually doing in your body

The first pen's job is adjustment, not weight loss. At 2.5 mg, most people experience only modest appetite suppression. That can feel anticlimactic, but it's the point: your gut is learning to handle slowed emptying and altered hormone signalling without being overwhelmed. The gastrointestinal side effects that most commonly cause people to stop Mounjaro early (nausea in particular) are significantly more manageable when the dose rises gradually from a low base.

After four weeks at 2.5 mg, the next step is typically 5 mg, and understanding what side effects to expect at the 5 mg stage can help you feel prepared before that first increase. Whether and when each subsequent increase happens depends on how you're tolerating the current dose. There's no fixed timetable that overrides clinical judgement; if side effects at 5 mg are making things difficult, staying there longer before moving to 7.5 mg is a legitimate option. Our guidance on dose increases covers when titration can be slowed and what your prescriber looks for.

The NHS tirzepatide medicines page notes that side effects are typically most noticeable after starting or following a dose increase, and that they often settle within days to a couple of weeks. Keeping the pen in the same spot in the fridge door each week (somewhere you'll notice it reliably) helps build the routine that makes the whole schedule easier to stick to.

Can the prescriber ever bypass 2.5 mg?

No legitimate prescriber working within the licensed prescribing information will start you above 2.5 mg. The titration schedule isn't a recommendation that can be upgraded with a patient request; it is the licensed pathway. Clinics that advertise higher starting doses as a premium option, or frame a faster start as a service advantage, are not following the evidence base or the SmPC.

It is worth distinguishing this from the separate question of whether someone who has previously been on Mounjaro can restart at a higher dose after a break. That is a clinical decision your prescriber makes by reviewing your treatment history, not something a patient can self-select. If you've been on treatment before and are wondering about whether restarting at 7.5 mg is ever appropriate, the answer involves your prescriber reviewing the evidence of your prior dose history.

For a full picture of how the dose schedule works from 2.5 mg through to 15 mg, the overview of what dose Mounjaro begins at sets out each step and the clinical reasoning behind the titration intervals.

What this means when you're ready to start

Understanding the starting dose helps set realistic expectations. The first four weeks are not wasted weeks; they are the foundation that makes the rest of the schedule tolerable. Most people who reach the higher therapeutic doses (10 mg, 12.5 mg, 15 mg) credit the steady step-up with keeping side effects manageable along the way.

Private treatment through a regulated service means no referral and no waiting list, subject to clinical suitability. The private eligibility threshold is generally BMI 30 or above, or BMI 27 or above with a weight-related condition such as high blood pressure or type 2 diabetes; lower thresholds may apply for some ethnic backgrounds under UK guidance. None of that changes the starting dose. For context on what private treatment typically costs at each stage, Mounjaro pricing explained sets out the market picture honestly, including what a legitimate price should include.

If you have questions about how your own medical history interacts with the titration schedule, that is exactly the kind of thing our prescribers work through with you at consultation. Speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered clinician.